Christopher LaGanke

Statistics

Publications

Citations

1.1K

H-Index

Active since

1998

Affiliations

NeuroRx Research (Canada)(Current)

Biogen (United States)

Cleveland Clinic

McGill University

Urology Associates

Christopher LaGanke is an author at NeuroRx Research (Canada) specializing in multiple sclerosis therapy, relapsing-remitting multiple sclerosis treatment, and multiple sclerosis.

Publications per year

1998–2023

Publications

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 192 citations · Full text

Medicine, Neurology, Pharmacology +9

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

Medicine, Pharmacology, Pharmacotherapy +11

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Tanuja Chitnis, Brenda Banwell, Ludwig Kappos et al. · The Lancet Neurology · 2021 · 81 citations

Medicine, Neurology, Pediatrics +12

1–5 of 14